# Intra-Cellular Therapies, Inc.

Intra-Cellular Therapies, Inc. is a company headquartered in Bedminster, NJ, United States.

## Company overview

- **Legal name:** Intra-Cellular Therapies, Inc.
- **Former names in filing history:** Intra-Cellular Therapies, Inc. (2013-09-05 to 2025-06-05); Oneida Resources Corp. (2013-02-08 to 2013-08-29)
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Bedminster, NJ, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001567514

## About

Intra-Cellular Therapies, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001567514, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2025-02-21, it reported annual revenue of USD 680,852,000; net income of USD -74,676,000; total assets of USD 1,366,912,000 for the fiscal period ended 2024-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2024 (period ended 2024-12-31)

- **Revenue:** $680.9M (USD 680,852,000)
- **Net income:** -$74.7M (USD -74,676,000)
- **Total assets:** $1.4B (USD 1,366,912,000)
- **Cash and equivalents:** $306.9M (USD 306,948,000)
- **Operating cash flow:** -$73.2M (USD -73,177,000)

### FY2023 (period ended 2023-12-31)

- **Revenue:** $464.4M (USD 464,370,000)
- **Net income:** -$139.7M (USD -139,674,000)
- **Total assets:** $728.3M (USD 728,295,000)
- **Cash and equivalents:** $147.8M (USD 147,767,000)
- **Operating cash flow:** -$124.2M (USD -124,199,000)

### FY2022 (period ended 2022-12-31)

- **Revenue:** $250.3M (USD 250,314,000)
- **Net income:** -$256.3M (USD -256,256,000)
- **Total assets:** $754.8M (USD 754,780,000)
- **Cash and equivalents:** $148.6M (USD 148,615,000)
- **Operating cash flow:** -$270.2M (USD -270,186,000)

### FY2021 (period ended 2021-12-31)

- **Revenue:** $83.8M (USD 83,803,017)
- **Net income:** -$284.1M (USD -284,125,666)
- **Total assets:** $489.9M (USD 489,922,096)
- **Cash and equivalents:** $92.4M (USD 92,364,990)
- **Operating cash flow:** -$259.5M (USD -259,543,485)
- **Later filings:** Revenue, Net income, Total assets, Cash and equivalents, Operating cash flow: shown as originally filed; later filings report different values for the same periods.

## Recent SEC filings

- Form 8-K — filed 2025-04-02 — period 2025-04-02 — 8-K
- Form 8-K — filed 2025-03-27 — period 2025-03-27 — 8-K
- Form 10-K/A — filed 2025-03-20 — period 2024-12-31 — 10-K/A
- Form 8-K — filed 2025-03-18 — period 2025-03-18 — 8-K
- Form 8-K — filed 2025-03-03 — period 2025-02-26 — 8-K
- Form 10-K — filed 2025-02-21 — period 2024-12-31 — 10-K
- Form 8-K — filed 2025-02-21 — period 2025-02-21 — 8-K
- Form 8-K — filed 2025-01-13 — period 2025-01-10 — 8-K
- Form 8-K — filed 2025-01-10 — period 2025-01-08 — 8-K
- Form 8-K — filed 2024-12-03 — period 2024-12-03 — 8-K
- Form 8-K — filed 2024-11-05 — period 2024-11-05 — 8-K
- Form 10-Q — filed 2024-10-30 — period 2024-09-30 — 10-Q

---

Updated: 2026-10-23T19:32:55Z

Canonical page: https://altss.com/profile/intra-cellular-therapies-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology